- Home
- Products
- Customized ADCs
- C. diff toxin B
- Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-MMAE ADC
Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2063)
This ADC product is comprised of an anti-C. diff toxin B monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- C. diff toxin B
- Alternative Names
- C. diff toxin B, Clostridium difficile Toxin B
- Overview
- Clostridium difficile Toxin B (tcdB or ToxB) is a glucosyltranferase which is known to innactivate Rho, Cdc42 and Rac within target cells. This toxin is encoded on a pathogenicity region of the C. difficile chromossome and is expressed during the log and stationary phases of growth in response to a variety of environmental stimuli.
- Overview
- Human Anti-C. diff toxin B IgG1-kappa antibody, Bezlotoxumab
- Generic name
- Bezlotoxumab
- Host animal
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-FLT1 (Icrucumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1153)
- Anti-CTLA4 (Ticilimumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1009)
- Anti-IL4R-SMCC-DM1 ADC (CAT#: ADC-W-1382)
- Anti-IL23A (Guselkumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1349)
- Anti-TNFRSF10A (Mapatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2419)
- Anti-FOLH1 (Capromab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1165)
- Anti-CD72-Mc-MMAF ADC (CAT#: ADC-W-612)
- Anti-NCA-90 (Lemalesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2167)
- Anti-TNF (Nerelimomab)-MC-MMAF ADC (CAT#: ADC-W-1858)
- Anti-TPBG-Mc-MMAD ADC-7 (CAT#: ADC-W-163)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2063. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2064 | Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2060 | Anti-C. diff toxin B (Bezlotoxumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2061 | Anti-C. diff toxin B (Bezlotoxumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2062 | Anti-C. diff toxin B (Bezlotoxumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2065 | Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2596 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2593 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2614 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2581 | Anti-CEACAM5-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2574 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2568 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2551 | Anti-CD74-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.